regdanvimab sold brand name regkirona human monoclonal antibody used treatment antibody directed spike protein developed medicine given infusion drip common side effects include infusionrelated reactions including allergic reactions regdanvimab approved medical use european union november european union regdanvimab indicated treatment adults require supplemental oxygen increased risk progressing severe march committee medicinal products human use chmp european medicines agency ema started rolling review data october ema started evaluating application marketing authorization monoclonal antibody regdanvimab regkirona treat adults require supplemental oxygen therapy increased risk progressing severe applicant celltrion healthcare hungary european medicines agency ema concluded regdanvimab used treatment confirmed adults require supplemental oxygen therapy high risk progressing severe november committee medicinal products human use chmp european medicines agency ema recommended granting marketing authorization european union regdanvimab regkirona treatment company applied authorization regkirona celltrion healthcare hungary regdanvimab approved medical use european union november regdanvimab international nonproprietary name httpsenwikipediaorgwikiregdanvimab